Growing technological advancements and military and occupational needs are expected to drive market expansion in the near future at a CAGR of 5.00% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published on the “Global US Anthrax Vaccine Market”.

The US Anthrax Vaccine market is estimated to register a CAGR of 5.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the US Anthrax Vaccine market— Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene, Inc, Biogenesis Bago S.A, Porton Biopharma Limited, Colorado Serum, Merial, Inc., Tiankang, Agrovet, and Bayer AG.

US Anthrax Vaccine Market Highlights

The US Anthrax Vaccine market has registered a CAGR of 5.00% during the forecast period and is estimated to reach USD 8.7 billion by 2032.

The market is driven by significant contracts from government organizations that provide consistent financing and demand for anthrax vaccines, such as the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (DoD). Additionally, a big obstacle preventing certain pharmaceutical companies from entering this specialized market is the exorbitant expense of developing, producing, and researching anthrax vaccines. Furthermore, there is a chance to grow the market beyond military contracts to include civilian populations, first responders, and high-risk professional groups in light of increasing worries about bioterrorism and new infectious illnesses. Moreover, healthcare providers and the public's reluctance to get anthrax vaccinations may be influenced by safety worries about the shots, including possible negative responses and side effects.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of US Anthrax Vaccine Market Research Report

Segment Analysis

The US Anthrax Vaccine market has been segmented based on vaccine type, applications, and distribution channel.

Based on the vaccine type, the market is segmented into cell-free PA vaccine, anthrax vaccine adsorbed (AVA), anthrax vaccine precipitated (AVP), and live attenuated vaccine. The cell-free PA vaccine segment was attributed to holding the largest market share in 2023. The protective antigen component of anthrax is the exclusive target of the single antigen strategy used in the Cell-Free PA Vaccine. This more efficient method might expedite time to market and save costs by streamlining the manufacturing, regulatory approval, and vaccine development procedures.

The US Anthrax vaccine market has been segmented based on applications into animal use and human use. In 2023, the animal use segment was anticipated to have the highest market share. Animal vaccination campaigns against anthrax aid in national biodefense and public health readiness by lowering the possibility of anthrax spreading from contaminated animals to people. Keeping cattle from becoming infected with the anthrax bacteria contributes to the protection of human populations from this pathogen.

Based on the distribution channel, the US Anthrax Vaccine market has been segmented into hospitals, pharmacies, and other distribution channels. The category for hospitals was predicted to hold the largest market share in 2023. Several hospitals could be chosen to serve as distribution hubs for government-run or public health authorities' stocks of anthrax vaccination. AVA may be distributed and stored by hospitals with sufficient handling and storage capacity as part of larger biodefense and disaster preparedness initiatives.

US Anthrax Vaccine Country Analysis

The continual research, distribution, and storage of anthrax vaccines is necessitated by the ongoing threat that anthrax poses to bioterrorism. Government agencies and public-private partnerships finance biodefense projects that drive the US anthrax vaccine market's innovation, research, and manufacture. Improving public health readiness for bioterrorism and anthrax epidemics is a top concern for US public health officials. The demand for anthrax vaccines is driven, and the market is supported by initiatives to manage stockpiles, emergency response plans, and immunization campaigns. In the US anthrax vaccine industry, there are several producers and suppliers, which encourages competition, product differentiation, and innovation. Companies are encouraged to engage in R&D, manufacturing capabilities, and commercialization efforts by competing for government contracts and meeting the demands of new markets, which propels market growth.

Key Findings of the Study

• The US Anthrax Vaccine market is expected to reach USD 8.7 billion by 2032, at a CAGR of 5.00% during the forecast period.


• Based on applications, the animal use segment was attributed to holding the largest market in 2023.


• Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene, Inc., Biogenesis Bago S.A, Porton Biopharma Limited, Colorado Serum, Merial, Inc., Tiankang, Agrovet, and Bayer AG are the key market players.